Search results for "Molecular-Weight"

showing 10 items of 72 documents

Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor.

2021

Hereditary angioedema (HAE) attacks are caused by excessive activation of the contact system. Understanding how the contact system is activated in HAE, especially in patients with normal C1 inhibitor (HAEnCI), is essential to effectively treat this disease. Contact system activation involves the cleavage of several proteins including Factor XII (FXII), high molecular weight kininogen (HK), prekallikrein, sgp120 (ITIH4) and C1 inhibitor (C1-INH) before the subsequent generation of bradykinin that mediates HAE. In this study, we evaluated the fragmentation and enzymatic activity of contact system proteins in HAEnCI plasma samples before and after contact system activation induced by incubatio…

0301 basic medicineAdultMalemedicine.medical_specialtyHigh-molecular-weight kininogenImmunologyProteinase Inhibitory Proteins SecretoryBradykininBradykininC1-inhibitorHereditary Angioedema Type III03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineInternal medicinemedicineHumansFragmentation (cell biology)Molecular BiologyBlood CoagulationFactor XIIbiologyKininogensPrekallikreinPrekallikreinEstrogensPlasminogenKallikreinMiddle Agedmedicine.diseaseCold Temperature030104 developmental biologyEndocrinologychemistryHereditary angioedemaFactor XIIbiology.proteinFemaleKallikreinsComplement C1 Inhibitor Protein030215 immunologyMolecular immunology
researchProduct

Blood rheology during chemotherapy in patients with ovarian cancer.

1998

The use of platinum based chemotherapy in ovarian malignancy and other cancer types is known to be associated with deep vein thrombosis. In a prospective study of 47 patients with ovarian cancer of International Federation of Gynecology and Obstetrics stage Ib-IV, serial rheological parameters were determined (plasma viscosity, red blood cell aggregation under conditions of stasis and low shear) in addition to hemoglobin, hematocrit, leukocytes, platelets, and fibrinogen. At the same time the incidence of deep vein thrombosis was recorded before, during six cycles of first line cisplatinum/epirubicin/cyclophosphamide chemotherapy, and 2 months thereafter (two-months check-up). Only six pati…

AdultErythrocyte Aggregationmedicine.medical_specialtymedicine.drug_classDeep veinBlood viscosityVenographyLow molecular weight heparinAntineoplastic AgentsHematocritGastroenterologyHemoglobinsLeukocyte CountInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesVeinCyclophosphamideAgedEpirubicinOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryPlatelet CountFibrinogenHematologyHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseBlood ViscosityThrombosisSurgerymedicine.anatomical_structureHematocritHemorheologyFemaleCisplatinbusinessEpirubicinmedicine.drugThrombosis research
researchProduct

Parallel reduction of plasma levels of high and low molecular weight kininogen in patients with cirrhosis

1999

SummaryLittle is known about the regulation of high-molecular-weight-kininogen (HK) and low-molecular-weight-kininogen (LK) or the relationship of each to the degree of liver function impairment in patients with cirrhosis. In this study, we evaluated HK and LK quantitatively by a recently described particle concentration fluorescence immunoassay (PCFIA) and qualitatively by SDS PAGE and immunoblotting analyses in plasma from 33 patients with cirrhosis presenting various degrees of impairment of liver function. Thirty-three healthy subjects served as normal controls. Patients with cirrhosis had significantly lower plasma levels of HK (median 49 μg/ml [range 22-99 μg/ml]) and LK (58 μg/ml [15…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyKininogen High-Molecular-WeightCirrhosisHigh-molecular-weight kininogenKininogen Low-Molecular-WeightSeverity of Illness IndexLiver diseaseLiver Function TestsInternal medicineBlood plasmaCholinesterasesHumansMedicineSerum AlbuminAgedKininogenbusiness.industryAlbuminHematologyBlood Coagulation DisordersMiddle Agedmedicine.diseaseLow-molecular-weight kininogenEndocrinologyProthrombin TimeFemaleLiver functionbusiness
researchProduct

Bemiparin improves the total antioxidant status in plasma

2008

The aim of this work is to test the protective effect of bemiparin (3500 I.U., s.c.) against oxidative stress in plasma from healthy volunteers. We have evaluated the total antioxidant activity in plasma, superoxide dismutase and glutathione peroxidase activities, and oxidized glutathione and malondialdehyde levels, in two groups: treated (n=20) and control (n=15). Blood samples were collected at: basal, 2, 4, 6, 8 and 10 h. Total antioxidant activity and antioxidant enzymes activity were higher in the treated group at 2-6 h. However, oxidized glutathione and malondialdehyde levels were lower in the treated group at same times. The results suggest that bemiparin exerts an early beneficial e…

AdultMaleAntioxidantmedicine.medical_treatmentPharmacologymedicine.disease_causeAntioxidantsSuperoxide dismutasechemistry.chemical_compoundBlood plasmamedicineHumansPharmacologychemistry.chemical_classificationGlutathione PeroxidasebiologySuperoxide DismutaseGlutathione peroxidaseHeparin Low-Molecular-WeightMalondialdehydeOxidative StressAntioxidant capacityEnzymeBiochemistrychemistryHealthbiology.proteinFemaleBiomarkersOxidative stressEuropean Journal of Pharmacology
researchProduct

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Deferment of Objective Assessment of Deep Vein Thrombosis and Pulmonary Embolism Without Increased Risk of Thrombosis

2004

Background: Treatment of patients with suspected deep vein thrombosis (DVT) or pulmonary embolism (PE) is problematic if diagnostic imaging is not immediately available. Pretest clinical probability (PCP) and D-dimer assessment can be used to identify patients for whom empirical protective anticoagulation is indicated. To evaluate whether PCP and D-dimer assessment, together with the use of low-molecular-weight heparins (LMWHs), allow objective appraisal of DVT and PE to be deferred for up to 72 hours, patients with suspected DVT and PE were prospectively examined. Methods: Patients identified with a high PCP or a moderate PCP with positive D-dimer test results received a protective full-do…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classDeep veinLow molecular weight heparinFibrin Fibrinogen Degradation ProductsD-dimerInternal MedicinemedicineHumansRisk factoranticoagulationAgedAged 80 and overVenous ThrombosisPatientVascular diseasebusiness.industrylow molecular weight heparinAnticoagulantdeep vein thrombosisuspected PEHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureD dimerFemalePulmonary EmbolismbusinessAlgorithmsFollow-Up StudiesArchives of Internal Medicine
researchProduct

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

2009

Introduction: We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures Methodology: Pre-operatively, patients discontinued VKA 5 +/- 1days; in those at low-risk for thrombosis, LMWH was given at a prophylactic dosage of 3.800 U.I. (nadroparin) or 4.000 U.I. (enoxaparin) anti-FXa once daily the night before the procedure. In patients at high-risk for thrombosis, LMWH was started early after VKA cessation and given at fixed sub-therapeutic doses (3.800 or 4.000 UI anti-FXa twice daily) until surgery. Post-operatively, LMWH was reinitiated 12 hours after procedure whil…

AdultMalemedicine.medical_specialtyBridging low molecular weight heparinTime FactorsVitamin Kmedicine.drug_classLow molecular weight heparinAdministration OralPostoperative HemorrhageRisk AssessmentDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRisk FactorsThromboembolismmedicineHumansProspective StudiesEnoxaparinProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)WarfarinAnticoagulantsNadroparinHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryLow Molecular Weight Heparin Fixed doses Chronic oral anticoagulation perioperative bridgingAnesthesiaSurgical Procedures OperativeNadroparinFeasibility StudiesFemaleWarfarinbusinessmedicine.drugFactor Xa Inhibitors
researchProduct

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

2014

Background— Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. Methods and Results— In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.…

AdultMalemedicine.medical_specialtyRE-COVER IIrecurrenceAntagonists & inhibitorsAdolescentvenous thromboembolismAntithrombinsDabigatranYoung AdultDouble-Blind MethodRisk FactorsPhysiology (medical)Internal medicinemedicineHumansdabigatrancardiovascular diseasesantagonists & inhibitorAgedacute venous thromboembolismHeparinbusiness.industryWarfarinFollow up studiesAnticoagulantsantagonists & inhibitors; hemorrhage; recurrence; thrombin; venous thromboembolism; warfarinHeparinHeparin Low-Molecular-WeightMiddle AgedthrombinSettore MED/11 - Malattie Dell'Apparato CardiovascolarewarfarinHeparin.low molecular weightPooled analysisAnesthesiaAcute Diseasebeta-AlanineBenzimidazolesFemaledabigatran; warfarin; acute venous thromboembolism; RE-COVER IIhemorrhageCardiology and Cardiovascular MedicinebusinessVenous thromboembolismFollow-Up Studiesmedicine.drug
researchProduct

Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).

2021

Objective Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions. Methods Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding. Results A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was …

AdultMalemedicine.medical_specialtySuperficial vein thrombosismedicine.drug_classDeep veinLow molecular weight heparinHemorrhage030204 cardiovascular system & hematology030230 surgeryFondaparinuxVaricose Veins03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsmedicineHumansProspective StudiesAgedAged 80 and overVenous Thrombosisbusiness.industryHazard ratioLeg UlcerAnticoagulantsHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeFondaparinuxLower ExtremityVenous InsufficiencySurgeryFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismStockings Compressionmedicine.drugFactor Xa InhibitorsEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
researchProduct

Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen.

1992

In a prospective, randomized, double-blind investigation of anticoagulant agents for prevention of deep vein thrombosis in patients undergoing operations at the lumbar-vertebral disc, 179 patients were randomly allocated to two groups. 87 patients received a fixed combination of low-molecular weight heparin 1,500 U-aPTT plus dihydroergotamine 0.5 mg (LMWH/DHE) once a day and additionally one injection of placebo per day, 92 patients received a fixed combination of sodium heparin 5,000 U plus dihydroergotamine 0.5 mg (HDHE) twice a day. Treatment was initiated two hours preoperatively in both groups and continued for at least seven days. Deep vein thrombosis (DVT), detected by the 125Iodine-…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep veinLow molecular weight heparinHemorrhageDihydroergotaminePostoperative ComplicationsDouble-Blind MethodRisk FactorsAntithromboticmedicineHumansProspective StudiesAgedLumbar Vertebraebusiness.industryHeparinAnticoagulantGeneral MedicineHeparinHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseThrombosisSurgeryRegimenDrug Combinationsmedicine.anatomical_structureAnesthesiaSurgeryFemaleNeurology (clinical)businessDihydroergotamineIntervertebral Disc Displacementmedicine.drugNeurosurgical review
researchProduct